See more : POSCO STEELEON Co., Ltd. (058430.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Puequ CO.,LTD. (9264.T) Income Statement Analysis – Financial Results
- Kovai Medical Center and Hospital Limited (KOVAI.NS) Income Statement Analysis – Financial Results
- Yoma Strategic Holdings Ltd. (Z59.SI) Income Statement Analysis – Financial Results
- Bellevue Group AG (BBN.SW) Income Statement Analysis – Financial Results
- Allianz SE (ALV.WA) Income Statement Analysis – Financial Results
Aclaris Therapeutics, Inc. (ACRS)
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.25M | 29.75M | 6.76M | 6.48M | 4.23M | 10.09M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 18.08M | 11.96M | 4.71M | 5.13M | 4.06M | 6.85M | 1.21M | 120.00K | 90.00K | 0.00 | 0.00 |
| Gross Profit | 13.17M | 17.79M | 2.05M | 1.35M | 172.00K | 3.24M | 476.00K | -120.00K | -90.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 42.14% | 59.80% | 30.29% | 20.81% | 4.07% | 32.12% | 28.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.38M | 77.81M | 43.81M | 31.73M | 64.90M | 63.01M | 39.79M | 33.48M | 15.34M | 6.51M | 3.49M |
| General & Administrative | 31.10M | 25.13M | 23.62M | 20.53M | 27.16M | 27.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 283.00K | 671.00K | 48.00M | 85.00K | 3.30M | 0.00 | 0.00 | 0.00 |
| SG&A | 31.10M | 25.13M | 23.62M | 20.53M | 27.83M | 75.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Other Expenses | 0.00 | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | 2.07M | 488.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 130.80M | 102.95M | 67.43M | 52.26M | 92.73M | 138.66M | 72.90M | 48.57M | 20.67M | 8.53M | 5.26M |
| Cost & Expenses | 128.61M | 114.91M | 72.15M | 57.39M | 96.78M | 145.51M | 74.11M | 48.57M | 20.67M | 8.53M | 5.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.00K | 16.00K | 21.00K |
| Interest Expense | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 863.00K | 797.00K | 923.00K | 1.32M | 1.59M | 1.32M | 402.00K | 120.00K | 90.00K | 12.00K | 11.00K |
| EBITDA | -117.57M | -84.36M | -65.06M | -48.20M | -90.84M | -80.78M | -53.45M | -48.57M | -20.67M | -8.52M | -5.25M |
| EBITDA Ratio | -376.22% | -267.74% | -607.08% | -785.44% | -1,751.83% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -97.36M | -85.15M | -65.38M | -50.91M | -111.06M | -135.41M | -72.42M | -48.57M | -20.67M | -8.53M | -5.26M |
| Operating Income Ratio | -311.55% | -286.21% | -967.08% | -785.44% | -2,627.35% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.51M | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | -15.99M | 488.00K | 104.00K | 16.00K | 21.00K |
| Income Before Tax | -88.85M | -86.91M | -90.87M | -51.34M | -113.54M | -132.74M | -70.35M | -48.08M | -20.56M | -8.52M | -5.24M |
| Income Before Tax Ratio | -284.32% | -292.11% | -1,343.96% | -791.98% | -2,686.11% | -1,315.41% | -4,180.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -367.00K | 1.75M | 23.42M | -182.00K | 29.31M | 2.68M | -1.83M | -120.00K | -90.00K | 0.00 | 0.00 |
| Net Income | -88.48M | -88.66M | -114.28M | -51.15M | -142.85M | -132.74M | -68.52M | -48.08M | -20.56M | -8.52M | -5.24M |
| Net Income Ratio | -283.15% | -298.00% | -1,690.30% | -789.17% | -3,379.47% | -1,315.41% | -4,071.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| EPS Diluted | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| Weighted Avg Shares Out | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
AllClear Repair Services Approved as Honeywell Authorized Service Center
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
American Clinical Research Services Announces Strategic Acquisition of Elixia
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports